IL1B and cryopyrin-associated periodic syndrome: Approved in 2009, canakinumab has shown therapeutic efficacy by selectively neutralizing IL-1β in various diseases, such as CAPS, tumor necrosis factor receptor-associated periodic syndrome (TRAPS), and reducing atherosclerotic cardiovascular risk in certain populations [7].